Atara Biotherapeutics, Inc.
EBVALLO (tabelecleucel)
Resolved
176days ago
FDA decision · Jan 12, 2026
What's at stake
An FDA complete response letter on EBVALLO (tabelecleucel) for its lead indication is in focus around Jan 12, 2026.
Primary source
· SEC 8-K
verified 14h ago
“the U.S. Food and Drug Administration issued a Complete Response Letter for the EBVALLO ™ (tabelecleucel) Biologics License Application.”